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TDP-43 is a 43-kD protein encoded by one of 
the multiple splicing isoforms of mRNAs from 
TARDBP, a gene highly conserved in eukaryotes 
from Caenorhabditis elegans to human (Wang et al., 
2004). It is an ubiquitously expressed nuclear 
protein (Wang et al., 2002) with a diverse set of 
activities in different biological processes, includ-
ing  DNA/RNA  binding,  repression  of  gene 
transcription,  and  regulation  of  alternative 
splicing of the CFTR premRNA (for review 
see Buratti and Baralle, 2008; Wang et al., 2008a). 
The characteristics of TDP-43 in cultured hip-
pocampal neurons have suggested that it may 
play a role in the regulation of neuronal plastic-
ity (Wang et al., 2008b). Loss of TDP-43 in   
human cells by RNAi resulted in dysmorphic 
nuclear shape, misregulation of the cell cycle, 
and apoptosis through the misregulation of the 
retinoblastoma protein (Ayala et al., 2008). 
Likely because of its involvement in multiple 
biological  processes, TDP-43  appeared  to  be 
required for early mouse embryogenesis (Wu   
et  al.,  2010).  Interestingly, TDP-43  has  been 
identified as the major disease protein for a range 
of neurodegenerative diseases, including fron-
totemporal lobar degeneration with ubiquitin+ 
inclusions (FTLD-U) and amyotrophic lateral 
sclerosis (ALS). In particular, it is the signature 
protein of the ubiquitinated inclusions (UBIs) 
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TDP-43 is a multifunctional DNA/RNA-binding factor that has been implicated in the 
regulation of neuronal plasticity. TDP-43 has also been identified as the major constituent 
of the neuronal cytoplasmic inclusions (NCIs) that are characteristic of a range of neurode-
generative diseases, including the frontotemporal lobar degeneration with ubiquitin+ inclusions 
(FTLD-U) and amyotrophic lateral sclerosis (ALS). We have generated a FTLD-U mouse 
model (CaMKII-TDP-43 Tg) in which TDP-43 is transgenically overexpressed in the forebrain 
resulting in phenotypic characteristics mimicking those of FTLD-U. In particular, the trans-
genic (Tg) mice exhibit impaired learning/memory, progressive motor dysfunction, and 
hippocampal atrophy. The cognitive and motor impairments are accompanied by reduced 
levels of the neuronal regulators phospho–extracellular signal-regulated kinase and  
phosphorylated cAMP response element-binding protein and increased levels of gliosis in the 
brains of the Tg mice. Moreover, cells with TDP-43+, ubiquitin+ NCIs and TDP-43–deleted 
nuclei appear in the Tg mouse brains in an age-dependent manner. Our data provide direct 
evidence that increased levels of TDP-43 protein in the forebrain is sufficient to lead to the 
formation of TDP-43+, ubiquitin+ NCIs and neurodegeneration. This FTLD-U mouse model 
should be valuable for the mechanistic analysis of the role of TDP-43 in the pathogenesis 
of FTLD-U and for the design of effective therapeutic approaches of the disease.
© 2010 Tsai et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Despite the rapidly accumulating data on the molecular 
and cellular properties of TDP-43 in relation to the formation 
TDP-43+ NCIs or UBIs (Johnson et al., 2008; Winton et al., 
2008; Zhang et al., 2009), a causative role of TDP-43 in the 
pathogenesis  of  FTLD-U  remains  undefined.  Biochemical 
analyses have revealed that TDP-43 is promiscuously modified/
processed in the affected regions of the brains and spinal cords 
of the FTLD-U and ALS patients, respectively. In particular, 
the  following TDP-43–derived  polypeptides  have  been   
detected on Western blots of the urea-soluble extracts from 
the pathological samples with TDP-43+ UBIs: (a) multiple 
species of high molecular weight, polyubiquitinated TDP-43; 
(b)  phosphorylated TDP-43  migrating  at  45  kD;  and   
(c) 25- and 35-kD C-terminal fragments of TDP-43 (Arai   
et al., 2006; Cairns et al., 2007; Kwong et al., 2007; Neumann, 
2009; Giordana et al., 2010). In addition, immunohistochem-
istry analysis of the pathological samples from FTLD-U and 
ALS patients has revealed the presence of disease cells with 
NCIs adjacent to TDP-43–depleted nuclei (Arai et al., 2006; 
Neumann, 2009). The depletion of the nuclear TDP-43 and 
the formation of the UBIs have been suggested to cause loss-
of-function of TDP-43 and cellular toxicity, thus leading to 
the pathogenesis of FTLD-U and ALS with the TDP-43+ 
UBIs (Kwong et al., 2007; Mackenzie and Rademakers, 2008; 
Wang et al., 2008a).
Using  a Thy-1  promoter, Wils  et  al.  (2010)  generated 
transgenic (Tg) mice with overexpression of human TDP-43 
in  the  neurons  of 
the central nervous 
system,  in  addition 
to  other  cell  types 
of these diseases (Arai et al., 2006; Neumann et al., 2006), 
which include the neuronal cytoplasmic inclusions (NCIs) 
and  neuronal  intranuclear  inclusions  (NIIs;  for  review  see 
Neumann, 2009; Neumann et al., 2007; Wang et al., 2008a).   
A causative role of TDP-43 in the pathogenesis of ALS with 
NCIs has been suggested by the association of >30 different 
point mutations of the TDP genes with this class of ALS pa-
tients (for review see Lagier-Tourenne and Cleveland, 2009).
FTLD-U patients of different subtypes are mainly charac-
terized by ubiquitin+, - and -synuclein NCIs (Mackenzie 
et al., 2006), and, to a lesser extent, NIIs, both of which are 
also TDP-43+ (Neumann, 2007, 2009; Wang et al., 2008a). 
FTLD-U is the most common neuropathological subtype of 
FTLD, which refers to a clinically, genetically, and patholog-
ically heterogeneous group of neurodegenerative disorders 
(Hodges et al., 2004). FTLD is the second most common 
form of dementia in people under the age of 65, after   
Alzheimer’s disease, with the prevalence estimated between 
3.3  and  25.4  cases  per  100,000  people  (Ratnavalli  et  al., 
2002). Mutations in the progranulin (PGRN) and VCP genes, 
respectively, have been identified in a portion of the familial 
cases of FTLD-U (for review see Cairns et al., 2007; Mackenzie 
et al., 2006). Clinically, FTLD is characterized by behavioral 
and/or language dysfunction (Neary et al., 1998). In addi-
tion, patients may display movement abnormalities such as 
Parkinsonism or motor neuron disease (MND; Kertesz et al., 
2000;  Lomen-Hoerth  et  al.,  2002;  Forman  et  al.,  2006). 
Prominent frontal and temporal lobe atrophy associated with 
neuronal loss and gliosis are also found in FTLD (Snowden   
et al., 2007). Currently, there is no drug available for the 
treatment of FTLD or FTLD-U (Vossel and Miller, 2008).
Figure 1.  Generation and characteriza-
tion of CaMKII-TDP-43 Tg mice. (A) Physi-
cal map of the CaMKII-TDP-43 fragment for 
pronuclei injection. The orientation of tran-
scription is indicated by the arrow. The posi-
tions of the short hybrid intron derived from 
an adenovirus splice donor, an immunoglobu-
lin G splice acceptor, and the SV40 poly(A) 
addition sequence (pA) are indicated. The 
approximate locations of the Southern blot-
ting and PCR probes are also indicated.  
Tg mice were identified by the presence of the 
4.4-kb KpnI fragment on the Southern blot 
and the 523-bp PCR band on gel. The restric-
tion sites on the map are as follows: K, KpnI; 
E, EcoRV; N, NotI; S, SfiI. (B) Genotyping of the 
Tg mice. The data from PCR (top) and Southern 
blotting (bottom) analysis of the tail DNAs are 
exemplified. NT represents the nontransgenic 
samples. (C) Western blotting of the protein 
extracts from the hippocampus, cortex,  
cerebellum, and spinal cord of the WT, NT, and 
Tg mice, respectively. (D) In situ hybridization 
patterns of TDP-43 transcripts in the brains of 
WT and TDP-43 Tg mice (Tg). Bars, 500 µm.  
(E) Immunostaining patterns of TDP-43 protein 
in the brains of WT and Tg mice. CA1, CA1 
layer; CA3, CA3 layer; DG, dentate gyrus. Bars, 
200 µm. Results in B–E are representative of 
three independent experiments.JEM VOL. 207, August 2, 2010 
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523 bp band in the PCR analysis and a 4.4 kb fragment in the 
Southern blotting analysis. Neither band was present in   
the non-Tg (NT) samples (Fig. 1 B). The identities of the   
homozygotes of the Tg mice were also confirmed by breed-
ing them with the NT mice (unpublished data).
Three independent Tg lines were generated, and they   
exhibited similarly elevated levels of TDP-43 expression (ap-
proximately twofold higher than the NT mice) as directed by 
the CaMKII promoter in the cortex and hippocampus, which 
was detected by Western blotting analysis (Fig. 1 C, top left 
and right). The TDP-43 protein levels in the cerebellum and 
spinal cord of the Tg mice were similar to those of the WT 
mice (Fig. 1 C, bottom left and right). Note the higher levels 
of TDP-43 in the hippocampus and cortex samples from the 
Tg mice. The similar levels of the TDP-43 protein in the hip-
pocampus or cortexes of the Tg+/ and Tg+/+ mice might be 
caused by a feedback regulatory mechanism on the protein 
level because the TDP-43 mRNA level of the Tg+/+ mice was 
approximately twofold of that of the Tg+/ mice (Fig. S1). 
The details of this observation require further examination. 
As confirmed by in situ hybridization experiments, the WT 
mice exhibited basal signals, whereas the TDP-43 Tg mice 
showed higher signals in both the hippocampus and cortex 
(Fig. 1 D). As expected, both the endogenous (Fig. 1 E, left) 
and the overexpressed, exogenous TDP-43 proteins (Fig. 1 E, 
right) were present in the hippocampus mainly in the neuro-
nal layers, as shown by immunohistochemical staining.
Impaired performances of the TDP-43 Tg mice  
in the Morris water maze and fear-conditioning tasks
We first used the water maze task to evaluate whether   
overexpression of TDP-43 in the hippocampus and cortex 
affected  the  learn-
ing/memory of the 
mice.  As  shown, 
the 2-mo-old Tg+/+ 
mice exhibited sig-
nificantly  impaired 
performance in the 
in which the Thy-1 promoter is active, including the thymo-
cytes, myoblasts, epidermal cells, and keratinocytes. Degenera-
tion of the cortical/spinal motor neurons associated with a 
spastic quadriplegia reminiscent of ALS and degeneration of 
the nonmotor cortical and subcortical neurons characteristic 
of FTLD were observed in their Tg mice (Wils et al. 2010). 
Furthermore, cellular aggregates (NCIs and NIIs) containing 
ubiquitinated and phosphorylated TDP-43, as well as the 25-kD 
TDP-43 fragment, were detected in association with the   
disease development and progression of these human TDP-43-
overexpressing Tg mice.
In  this  study,  we  report  the  generation  of  a  FTLD-U 
mouse model with Tg overexpression of TDP-43 in the hippo-
campus, cortex, and striatum with use of the Ca2+/calmodulin-
dependent kinase II (CaMKII) promoter. These Tg mice have 
developed learning and memory deficits, as well as impair-
ment of their motor functions. The brains of the Tg mice are 
also characterized with a reduce volume of the hippocampus, 
gliosis, and TDP-43+, ubiquitin+ NCIs. In interesting connection 
with the finding that TDP-43 expression is up-regulated in 
some FTLD-U patients (Chen-Plotkin et al., 2008; Mishra et al., 
2007; see Discussion), our data suggest that changes of the ho-
meostatic concentration of TDP-43, in particular the increase of 
its protein level, in specific types of cells could be a primary cause 
leading to the development of FTLD-U, and likely other 
neurodegenerative diseases with TDP-43+ UBIs as well.
RESULTS
Generation of Tg mice
To test whether elevated expression of TDP-43 in the fore-
brain could be a cause for the generation of the various dis-
ease phenotypes as observed in FTLD-U patients, we have 
constructed Tg mouse lines carrying full-length mouse TDP-43 
cDNA under the transcription control of a 8.5 kb promoter 
region of the CaMKII gene (Mayford et al., 1996; Fig. 1 A). 
Genotyping  by  PCR  and  Southern  blotting  was  used  to 
identify the transgene-positive mice of the founders and their 
progenies, as exemplified in Fig. 1 B. DNA samples from both 
the heterozygotes+/ and homozygotes+/+ of the Tg mice gave a 
Figure 2.  Behavioral performances of 
CaMKII-TDP-43 Tg mice. (A) Water maze 
tests of 2-mo-old WT and TDP-43 Tg mice. 
The learning/memory capabilities are  
expressed as the latencies exhibited in six 
consecutive sessions of the test. Results  
represent the mean ± SEM of three indepen-
dent experiments (n = 20 mice/group).  
(B) Comparison of the cognitive functions of  
2-mo-old WT and Tg mice in the fear- 
conditioning task. (C) Locomotor activity test 
of 2-mo-old WT and Tg mice. Results in B and 
C represent the mean ± SEM of three inde-
pendent experiments and (n = 16 mice/group). 
(D) Abnormal limb-clasping of a 6-mo-old  
Tg mouse in comparison to a WT mouse  
when suspended by their tails. Results are 
representative of five independent experi-
ments. (E) Rotarod tests of WT and Tg mice. 
The time until drop from the rotating rod  
(20 r.p.m.) are shown for mice at 2, 4, and 6 mo 
of age. (F) Performance of mice in 1-h novel 
object recognition tests. The results represent 
the mean ± SEM of three independent experi-
ments (n = 10 mice/group). *, P < 0.05.1664 New mouse model of neurodegenerative disease | Tsai et al.
3.18 ± 0.30; Tg, 4.99 ± 0.25; ***, P = 0.0006; Fig. 3 B) 
was also detected but not the rise time constant (WT, 1.80 
± 0.08; Tg, 1.81 ± 0.04; P = 0.88; Fig. 3 B). These data in-
dicated that the receptor gating properties contributing to 
the EPSC amplitude and that decay kinetics were altered 
in the TDP-43 Tg mice.
test (compare the latencies of the Tg mice to those of the WT 
mice in Fig. 2 A, and to the NT littermates as shown in Fig. S2). 
Because the heterozygous+/ and homozygous+/+ Tg mice 
exhibited similar extents of impairment in their learning/
memory capabilities (Fig. S2), we used the homozygous Tg+/+ 
mice for all subsequent behavior tests and other experimental 
analyses. As shown in Fig. 2 B, the impairment of the 
learning/memory capabilities of the Tg+/+ mice were also   
revealed by the fear-conditioning task. Thus, the data from 
these two cognition tests together indicated that overexpres-
sion of TDP-43 in the hippocampus and cortex of the mice 
significantly impaired their learning/memory capabilities.
Abnormal limb-clasping and impaired performance  
of the TDP-43 Tg mice in the rotarod test
We have also analyzed the motor functions of the TDP-43   
Tg mice. The Tg mice were born normally and their sponta-
neous locomotor activities were normal at the age of 2 mo 
(Fig. 2 C). However, at the age of 6 mo, TDP-43 Tg mice 
showed limb-clasping reflexes when being suspended by their 
tails, whereas the control mice extended their limbs (Fig. 2 D). 
This abnormal reflex was often observed in mouse models of 
other neurodegenerative diseases, e.g., the Huntington disease 
(HD; Mangiarini et al., 1996). The mice were further sub-
jected to the rotarod test, and the results indicated that they 
were severely impaired in motor coordination, balance, and 
grip strength at the age of 6 mo (n = 10; P < 0.05), but not at 
2 or 4 mo (Fig. 2 E). The data of Fig. 2 (C–E) showed that the 
TDP-43 Tg  mice  developed  progressive  motor  behavioral 
deficits at the age of 6 mo. Because of the deficiency of the 
motor functions of the 6-mo-old TDP-43 Tg mice, the mice 
were also subjected to the novel object recognition test. As 
shown in Fig. 2 F, the 6-mo-old TDP-43 Tg mice were still 
deficient in the learning/memory capabilities, just like the   
2-mo-old Tg mice.
Electrophysiology analysis of TDP-43 Tg mice
In view of the impairment of the learning/memory of the 
TDP-43 Tg mice, we have performed electrophysiology analysis 
of their long-term potentiation (LTP) in comparison to the 
WT mice. LTP between the Schaffer collaterals and principal 
CA1 pyramidal neurons in the hippocampal slices prepared 
from the mice were measured. In correlation with the learning/
memory test experiments (Fig. 2), tetanic stimulation of the 
Schaffer collaterals resulted in robust LTP in slices from the 
WT mice. However, the slices from the TDP-43 Tg mice had 
impaired LTP maintenance for 60 min after the LTP induc-
tion (Fig. 3 A).
We also recorded the miniature excitatory postsynaptic 
current (mEPSC) from DIV 12–15 cultured hippocampal 
neurons (Fig. 3 B). No significant difference in the mEPSC 
frequencies could be detected (WT, 3.16 ± 0.65; Tg, 4.59 
± 0.83; P = 0.20; Fig. 3 B). However, significant difference 
existed between the mEPSC amplitudes of the WT and Tg 
mice (WT, 47.30 ± 2.56; Tg, 39.52 ± 2.96; *, P = 0.03; Fig. 3 B). 
Significant  difference  in  the  decay  time  constant  (WT,   
Figure 3.  Electrophysiology study of the CaMKII-TDP-43 Tg mice. 
(A) Attenuated LTP in the hippocampus of 2-mo-old CaMKII-TDP-43 Tg 
mice. LTP was induced by strong tetanus stimulation in the stratum radia-
tum layer of CA1. Results represent the mean ± SEM of three independent 
experiments (n = 18 mice/group). (B) Recording of altered mEPSCs in the 
primary hippocampal culture of CaMKII-TDP-43 Tg mice. Whole-cell voltage 
clamp recordings of cultured hippocampal neurons (12–15 DIV) from the 
WT and TDP-43 Tg mice were performed. Representative traces of the  
mEPSCs recorded from the neurons are shown on top. The frequencies, ampli-
tudes, decay , and rise  of the mEPSCs are shown in the histograms. *, P < 
0.05; ***, P < 0.001. The scale bars are 50 pA and 1 s, respectively. Results 
represent the mean ± SEM of three independent (n = 10 mice/group).JEM VOL. 207, August 2, 2010 
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the central nervous system and it is   
elevated  in  microglia  during  gliosis 
(Moisse et al., 2009a,b). Interestingly, 
in  recent  models  of  nerve  injury 
(Moisse et al., 2009a,b), it was found 
that axotomy caused both increase of 
TDP-43  and  decrease  of  PGRN  in 
the  neurons,  whereas  the  level  of 
PGRN in the surrounding activated microglia was increased. 
Thus, likely there could also be a decrease of PGRN in the 
TDP-43–overexpressing neurons of the Tg mouse forebrains, 
which  would  compensate  for  the  increase  of  the  PGRN 
amount in the activated microglia. Future experimentation 
should clarify this point.
Interestingly, the protein levels of the glutamic acid de-
carboxylase 67 (GAD67) and glial fibrillary acidic protein 
(GFAP) were also increased, by approximately twofold, in 
the cortex and hippocampus of the TDP-43 Tg mice. Of the 
two, GAD67 was known as the principal enzyme for synthe-
sis of the major inhibitory neurotransmitter -aminobutyric 
acid (GABA) in the brain. Its elevated expression in TDP-43 
Tg mice was further confirmed by double immunostaining of 
GAD67 and TDP-43 in the primary neuron cultures from 
both the Tg mice and the controls (Fig. 4 B). As seen, higher 
immunostaining signals of GAD67 were present in both the 
soma and the processes of the neuronal cells of the Tg mice 
than those of the WT controls (Fig. 4 B, compare the images 
in the right column to those in the left column), whereas the 
levels of the neuron-specific nuclear protein (NeuN) were 
similar between the Tg and control mice (unpublished data). 
In consistency with the immunostaining data of GAD67, re-
lease of the GABA neurotransmitter was also increased in the 
Figure 4.  Alterations of the levels of 
learning/memory-associated proteins in 
CaMKII-TDP-43 Tg mice. (A) Western blot 
analysis of different proteins in extracts pre-
pared from isolated cerebral cortex and hip-
pocampus of 2-mo-old WT and Tg mice (n = 2 
mice/group). Results are representative of 
three independent experiments. Quantitative 
analysis of the Western blot data are shown 
in the lower portion of A. (B) Immunostaining 
analysis of GAD67 expression and measure-
ment of GABA release. The primary hippocam-
pal neuron cultures of the WT (left) and 
TDP-43 Tg (Tg, right) mice were double-
stained with anti- GAD67 (green) and anti–
TDP-43 (red). Bars, 50 µm. The statistical 
comparison of the relative GAD67 intensities 
of GAD67+ cells of the WT and Tg mice is 
shown in the left histogram below the confo-
cal images. The data represent the mean ± 
SEM of three independent experiments  
(n = 20 mice/group). Shown in the lower right 
histogram is the statistical comparison of the 
GABA levels of the WT and Tg mice (n = 5;  
P < 0.05).
Decreased levels of phosphorylated extracellular signal-
regulated kinase and phosphorylated cAMP response 
element-binding protein and increased levels of GFAP, 
GAD67, and GABA in the hippocampus and cortex  
of TDP-43 Tg mice
In view of the impaired performances of the TDP-43 Tg 
mice in the learning/memory tests and their lowered LTP 
(Figs. 2 and 3), we have checked the levels in the hippocam-
pus and cortex of several major candidate proteins known to 
be involved in different signal transduction pathways regulat-
ing learning/memory (Kandel, 2001). Although the protein 
amounts  of  CaMKII,  protein  kinase  A,  growth-associated 
protein 43 (GAP43), synaptophysin (SYP), and postsynaptic 
density 95 (PSD95), respectively, were similar between TDP-
43 Tg mice and the WT controls, the levels of both pERK 
and its downstream target pCREB (Carlezon et al., 2005) in 
the TDP-43 Tg mice were decreased, as shown by the West-
ern blots and histogram in Fig. 4 A.
It should be noted that the level of PGRN in the fore-
brains of the Tg mice was similar to that of the WT mice 
(Fig. 4 A). It is not clear at the moment why the level of 
PGRN was not increased in the FTLD-U mouse brains in 
view of the elevated level of brain GFAP/gliosis in these 
mice. PGRN is expressed in neurons and microglia within 1666 New mouse model of neurodegenerative disease | Tsai et al.
Brain atrophy of the Tg mice
To examine whether brain atrophy developed in the Tg mice 
as in the FTLD-U patients, we first used MRI to measure the 
volume of the mouse hippocampus. The result showed that 
the volumes of the hippocampi of 6-mo-old Tg mice were 
17% less than those of the control mice (n = 5 for each group; 
P < 0.05). This range of the shrinking was similar to that   
of the frontal and temporal atrophy observed in some of   
the FTLD patients (Barnes et al., 2006; Snowden et al., 2007). 
In parallel with the MRI study, we also examined the brain 
weights and the cortex neuronal numbers of the mice. The   
results showed that there was neuronal loss in the 6-mo-old   
Tg mice. On average, the brain weight of the Tg mice was 
12% (n = 5; P < 0.05) less than the WT mice (Fig. 7 A), and 
the number of the cortical neurons was reduced by 24%   
(Fig. 7 B). The neuronal loss might result in part from apop-
tosis of the neurons in the Tg mouse brains. Indeed, apoptotic 
nuclei were detected, by TUNEL staining, in the brains of   
the 6-mo-old Tg+/+ mice (Fig. 7 C), and this was accompa-
nied with increases of the amounts of both the total and   
active caspase-3 (Fig. 7 D).
forebrains of the TDP-43 Tg mice (Fig. 4 B, bottom right). 
The results of Fig. 4 suggested that overexpression of TDP-43 
impaired the learning/memory of the TDP-43 Tg mice, in 
part by disrupting the phosphorylation of ERK, but also by 
up-regulating the inhibitory neurotransmitter GABA.
Neuropathology of the TDP-43 Tg mouse brains
In addition to the behavioral, electrophysiological, and gene 
expression abnormalities described in Figs. 2–4, the TDP-43 
Tg mice also exhibited several neuropathological characteris-
tics similar to those of the FTLD-U patient brains. First, reac-
tive gliosis manifested by increased expression of the astrocytic 
marker GFAP has been known as a prominent pathological 
feature of FTLD (Martin et al., 2001; Tan et al., 2005). As 
shown by Western blotting, the level of the GFAP protein 
was increased in the TDP-43 Tg mice (Fig. 4 A, bottom).
Consistent with this, pronounced increases of the signals of 
anti-GFAP immunostaining were observed in both the hip-
pocampus (HP) and the cortex (CX) of the Tg+/+ mice as 
compared with the WT controls (Fig. 5 A).
Second, Western blotting analysis revealed the presence 
of the high molecular weight TDP-43 species, presumably 
the polyubiquitinated TDP-43, as well as the enrichment 
of the 25- and 35-kD fragments in the urea-soluble frac-
tion of brain extracts from the 6-mo-old Tg mice (Fig. 5 B). 
This pattern on the Western blot was much less prominent 
in samples prepared from the 2-mo-old Tg mice, and it was 
not observed in those prepared from the WT mice (Fig. 5 B). 
Note that the high molecular weight TDP-43 species (***) 
and the 25-kD (*) and 35-kD (**) fragments of TDP-43 
are prominent in the 6-mo-old Tg+/+ mice, but not in the 
2-mo-old mice. The 65-kD band (open triangle) has also 
been observed by others on immunoblots of extracts from 
cell lines and from patient lymphocyte lysates (Winton   
et al., 2008; Corrado et al., 2009), but its significance is not 
yet clear.
We  also  performed  immunofluorescence  staining  to 
examine  the  subcellular  distribution  of  TDP-43  in  the 
Tg+/+ mouse brains in comparison to the WT mice. As 
shown in Fig. 6 A, TDP-43 was mainly detected in the 
nuclei,  which  were  positively  stained  with  both  anti-
NeuN and DAPI, of unaffected neurons of the TDP-43 
Tg mouse brains. Notably, however, TDP-43 was absent 
from the nuclei of neurons with TDP-43+ NCIs (Fig. 6 A, 
arrows  in  two  leftmost  bottom  images).  The  TDP-43+ 
NCIs were not observed in the brains of the WT mice, as 
exemplified  in  Fig.  6  A  (right,  WT  images).  Overall, 
15–20%  of  the  neurons  in  the  cortexes  of  the  Tg+/+ 
mice contained the TDP-43+ NCIs. Finally, antiubiquitin 
immunostaining showed that the TDP-43+ NCIs in the 
6-mo-old Tg mouse brains were also positive for the pres-
ence of ubiquitin (Fig. 6 B). Overall, the patterns from the 
proteinopathy analysis of the TDP-43 Tg mice, as displayed 
in Figs. 5 B and 6, were strikingly similar to those reported 
for the pathological FTLD-U brain samples with TDP+-
UBIs (for review see Forman et al., 2007).
Figure 5.  Neurodegeneration of the brains of CaMKII-TDP-43  
Tg mice. (A) Representative immunofluorescent images showing GFAP 
staining (green) in the hippocampus and cortex (CX) of 2-mo-old TDP-43 
Tg and WT mice. Nuclei were labeled by DAPI (blue). CA1, CA1 layer; CA3, 
CA3 layer; DG, dentate gyrus. Bars, 100 µm. (B) Representative Western 
blotting patterns of the urea-soluble fractions of the brain extracts from 
the cortexes and hippocampi of the WT mice and Tg+/+ mice at 2 mo and 
6 mo, respectively. The arrow points to the unmodified form of TDP-43. 
Results in A–C are representative of five independent experiments.JEM VOL. 207, August 2, 2010 
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impairment of learning/memory ca-
pabilities, the progressive loss of the 
motor  neuron  function,  abnormal 
LTP  from  the  electrophysiological 
measurement, the increase of gliosis, 
the alternation of the expression levels 
of proteins known to be involved in 
learning/memory, the reduction of the 
hippocampus  volume,  and,  notably, 
the  TDP-43+-UBI–associated  pro-
teinopathological  features  (Table  I). 
These changes in the CaMKII-TDP-
43 Tg mice are strikingly similar to the neurological and 
pathological features of the FTLD-U patients (Kwong et al., 
2007; Vossel and Miller, 2008).
The Tg mice have displayed a pattern of age-dependent 
loss of the motor function. In respect to this, the FTLD and 
the MND appear to overlap at several levels, and the FTLD 
patients share clinical features of MND. It should be noted 
here that only a portion of the FTLD patients would develop 
MND (Elman et al., 2008). Development of the motor behav-
ioral deficits in the TDP-43 Tg mice at 6 mo of age (Fig. 2, 
D and E) parallels the progressive loss of the motor function 
in the FTLD patients. As deduced from studies of different 
MNDs, including the ALS (Kwong et al., 2007; Elman et al., 
2008),  MND  could  be  clinically  manifested  by  signs  and 
symptoms caused by degeneration of the upper motor neu-
rons in the motor cortex, lower motor neurons in the brain-
stem and spinal cord, or both. However, the size and number 
of the motor neurons in the spinal cords of the Tg mice are 
not significantly different from those of the WT (Fig. S4). 
This is not surprising in view of the forebrain neuron speci-
ficity of the CaMKII promoter used by us. Thus, the motor 
dysfunction of the CaMKII-TDP-43 Tg mice most likely 
have resulted from damage in the neuronal circuit in the 
forebrain, which include the not so well-defined rodent   
motor cortex (O’Leary et al., 2007), and the corticospinal tract, 
caused by the CaMKII promoter-directed TDP-43 overex-
pression. It is also possible, but relatively unlikely because of 
Life span of the Tg mice
Finally, we measured the survival rates of the mice. The data, 
as shown in Fig. S3, indicated that the Tg+/+ mice had shorter 
lifespan, with a mean survival of 495 d, than the WT ones, 
which had an average survival of 632 d.
DISCUSSION
In this study, we have generated Tg mice with overexpres-
sion of mouse TDP-43 in the central nervous systems, includ-
ing the hippocampus and cortex, under the control of the 
CaMKII promoter. This promoter has been used before to 
overexpress other proteins in mice and thus establish different 
mouse models. However, each of these Tg mouse models 
exhibits unique phenotypes. For example, overexpression of 
either CREB (Kida et al., 2002) or NR2b (Tang et al., 1999) 
enhances  the  learning/memory  capabilities  of  the  mice, 
which is consistent with the known roles of these factors in 
learning/memory. On the other hand, overexpression of the 
methyl-CpG–binding protein 2 (MeCP2) leads to a motor 
dysfunction phenotype, but it has no effect on the cognitive 
function of the mice (Alvarez-Saavedra et al., 2007). Note-
worthily,  CaMKII  promoter-directed  overexpression  does 
not necessarily affect the mouse behaviors, as exemplified by 
the  Tg  mice  study  of  the  sulfonylurea  receptor,  or  SUR 
(Hernandez-Sánchez et al., 2001). In the case of TDP-43, its 
overexpression has resulted in several molecular, cellular, and 
phenotypic changes in the mice. These changes include the 
Figure 6.  Immunofluorescence staining 
analysis of TDP-43 distribution in the 
neurons of the mouse brains. (A) The brain 
sections of the WT and Tg mice were 
costained with anti–TDP-43 (red), anti-NeuN 
(green), and DAPI (blue). TDP-43+ NCIs are 
indicated by arrows. One neuron each in the 
Tg+/+ and WT samples (boxed) was magnified 
in the lower right corners (n = 5 mice/group). 
Bars, 20 µm. (B) Representative immunostain-
ing pattern of a 6-mo-old Tg+/+ mouse brain 
section exhibiting neuronal cells with TDP-43 
(green)-containing NCIs that are also positive 
for the anti-ubiquitin (Ub) staining (red,  
arrows). High magnification photos of one of 
the cells with TDP-43+, Ub+ NCIs are shown in 
the lower right corners . Bars, 20 µm.1668 New mouse model of neurodegenerative disease | Tsai et al.
activities in cell cultures, e.g., transcription (Ou et al., 1995; 
Wang et al., 2002), alternative splicing (Buratti and Baralle, 
2001; Bose et al., 2008), cell cycle progression (Ayala et al., 
2008), etc., it is expected that the phenotypes of the Tg mice 
result from the alternation/ modifications of multiple biolog-
ical processes as mis-regulated by the overexpressed TDP-43 
in the cortex and hippocampus. It should be noted here that 
one of our previous studies has shown that TDP-43 is distrib-
uted in the dendrites of cultured hippocampal neurons as 
granules/RNA granules (Wang et al., 2008b). However, we 
have detected no apparent difference in either the distribu-
tion pattern or the number of the TDP-43 granules between 
cultured hippocampal neurons prepared from Tg and WT 
mice (unpublished data).
In addition to the behavioral phenotypes, the TDP-43 
Tg mice also exhibited patterns of neuropathology similar to 
those of FTLD-U (Arai et al., 2006; Kwong et al., 2007; 
Neumann,  2009)  except  for  the  apparent  absence  of  the 
phosphorylated 45kD TDP-43 (Fig. 5).Specifically, neurons 
with  TDP-43  depleted  nuclei  and  cytoplasmic  TDP-43+, 
ubiquitin+ inclusions (UBIs) are present in brain sections of 
the 6-mo-old Tg mice, although they could not be detected 
in the 2-mo-old Tg mice (Fig. 6 A and B, and Table I). This 
age-dependent pattern of immunohistochemistry analysis is 
in good correlation with the immunoblotting data showing 
the enrichment of the high molecular weight TDP-43 species, 
presumably the polyubiquitinated TDP-43, and the 25- and 
35-kD TDP-43 fragments in the urea-soluble fractions of the 
brain extracts from 6-mo-old Tg mice (Fig. 5 B and Table I). 
Thus, it seems that the appearance of the insoluble TDP-43+ 
UBIs is a priori for the loss of the motor functions, but not 
the cognitive functions, in the mouse model. On the other 
hand, the appearance of the NCIs could just be a secondary, 
age-dependent phenomenon and that some other still un-
identified process is responsible for the motor dysfunction of 
the 6-mo-old Tg mice. The basis for this differential correla-
tion and whether it exists during the development of the   
human FTLD-U cases require further investigation.
Overall, we have demonstrated that Tg overexpression of 
TDP-43 in the forebrains of mice leads to development of 
molecular,  cellular,  behavioral,  and  proteinopathological 
characteristics similar to those identified in FTLD-U. Signifi-
cantly, there are FTLD-MND patients whose brain TDP-43 
mRNA levels are higher than the normal controls (Mishra   
et al., 2007). A global gene expression study has also found 
higher level of TDP-43 mRNA in several cases of PGRN 
mutation–positive  FTLD-U  (Chen-Plotkin  et  al.,  2008). 
Notably, immunoblotting analysis of lysates from some ALS 
pathological samples and myopathic muscles with TDP-43+ 
inclusions has also revealed higher TDP-43 protein levels 
than the normal controls (Kabashi et al., 2008; Weihl et al., 
2008). Thus, our data on the CaMKII-TDP-43 Tg mice sug-
gest that the elevation of the level of TDP-43 protein could 
be one of the primary causes leading to the pathogenesis of 
neurodegenerative diseases with TDP-43+ inclusions. After 
this scenario, different animal models could be generated by 
the CaMKII promoter specificity, that the motor dysfunction 
originated from some defects in the muscle of the Tg mice.   
Future detailed analysis of the CaMKII-TDP-43 Tg mice could 
clarify and differentiate among the aforementioned possibilities.
The CaMKII-TDP-43 Tg mice also exhibit cognitive im-
pairments as reflected by the Morris water maze test (Fig. 2 A), 
fear conditioning task (Fig. 2 B), novel object recognition test 
(Fig. 2 F), and LTP electrophysiological recording (Fig. 3). 
Related to this, the learning/memory deficiency in the FTLD 
patients is the major factor leading to the dysfunctions of their 
social behavior and language (Lillo and Hodges, 2009). As a 
preliminary investigation of the molecular and cellular basis 
of the effect of the overexpressed TDP-43 on the cognitive 
functions, we have examined the expression levels of several 
molecular markers of neuronal plasticity. The results (Fig. 4) 
indicate that overexpression of TDP-43 has led to the de-
creases of both p-ERK and p-CREB (Fig. 4), and likely down-
stream targets such as BDNF (Kandel, 2001). Furthermore, the 
enhanced gliosis, as observed in the Tg mice (Fig. 5 A), is also 
known to impair learning/memory (Ridet et al., 1997). Be-
cause overexpression of TDP-43 affects a range of biological 
Figure 7.  Neuronal loss and apoptosis in the brains of the Tg mice. 
(A) Reduction of the brain mass of the 6-mo-old Tg mice. Whole brains 
were dissected and weighed. n = 5; P < 0.05. (B) Loss of neurons in the 
cortexes of the Tg mice. Coronal brain sections from 6-mo-old Tg and  
WT mice were immunostained with anti-NeuN. The average number of the 
neurons in the cortexes of the Tg mice was compared with that of the WT 
mice (right; n = 5 for each group and P < 0.05). Bars, 100 µm. (C) TUNEL 
assay of the brains of 6-mo-old Tg mice. Apoptotic nuclei are shown in 
green (arrows) and DAPI staining in blue. (D) Western blots of total brain 
extracts (cortexes + hippocampi) of 6-mo-old WT and Tg mice showing 
levels of total and active caspase-3 (n = 5 mice/group). Bars, 20 µm.JEM VOL. 207, August 2, 2010 
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CaMKII promoter in our study has allowed the detection and 
follow up of pathogenesis development of the cognitive be-
haviors and motor function of the mice from their youth to 
over 2 yr of age. In addition, several hallmarks of FTLD-U, 
including the cognitive dysfunction, the hippocampal atrophy, 
and the progressive appearances of the 35- and 25-kD frag-
ments and the high molecular weight species of TDP-43 in 
the urea-soluble fraction of the disease forebrains (Table I) 
could be observed in these mice. Thus, although the mice 
generated by Wils et al. (2010) are more suitable for studies of 
neurodegeneration reminiscent of ALS, our CaMKII-TDP-
43 Tg mice are ideal for future detailed pathological/clinical 
analysis and drug/therapeutic development for FTLD-U.
MATERIALS AND METHODS
Construction and generation of CaMKII-TDP-43 Tg mice. To gener-
ate the Tg mice of FVB/N background, a 1,245-bp full-length mouse   
TDP-43 cDNA (available from GenBank/EMBL/DDBJ under accession no. 
NM_145556) was cloned into the EcoRV site of pNN265, a modified form 
of pcDNAI/Amp provided by E. Kandel (Columbia University, New York, 
NY;  Mayford  et  al.,  1996). A  2.7-kb  NotI  fragment  was  isolated  from 
pNN265 and cloned into the NotI site of the vector pMM403 containing 
8.5 kb of the mouse CaMKII promoter region (also provided by E. Kandel; 
Mayford et al., 1996), resulting in pCaMKII-TDP-43. An 11.2-kb SfiI fragment 
tissue or cell type-specific overexpression of TDP-43 for the 
basic as well as translational studies of other neurodegenera-
tive diseases with TDP-43+ UBIs.
It is interesting to compare a few aspects of this study with 
that by Wils et al. (2010). First, the data from the two studies 
together provide a strong support for the notion that elevated 
level of TDP-43 suffices the induction of neurodegeneration 
in mice, and very likely it is also responsible for the generation 
and  development  of  the  neurodegenerative  diseases  with 
TDP-43  proteinopathies,  in  humans.  Second,  both  studies 
have identified TDP-43–containing NCIs and activation of 
caspase-3 in association with neuronal apoptosis. Third, both 
studies have detected the appearances of the 35- and 25-kD 
C-terminal fragments of TDP-43 along the course of the 
pathogenesis development. Finally, Wils et al. (2010) used   
the Thy-1 promoter to direct the TDP-43 overexpression in 
the mice, which is active in a wider range of different types of 
cells, including neurons of the central nervous system, the 
muscle cells, the immune T cells, etc., and they characterized 
mainly the motor neuron dysfunction– and muscle defect–
related pathology and behavioral phenotypes of the Tg mice, 
such as the spastic paralysis, muscle wasting, reduced move-
ment,  etc.  However,  use  of  the  forebrain  neuron–specific 
Table I.  Summary of the molecular, cellular, and behavioral changes in TDP-43 Tg+/+ mice as compared to the WT
2-mo Tg 6-mo Tg
Cognitive functions
Water maze test decrease na
Fear conditioning task decrease na
Novel object recognition test decrease decrease
Motor functions
Limb-clasping reflex similar to WT increase
Rotarod testing similar to WT decrease
LTP decrease na
Gliosis Anti-GFAP staining na increase
Expression levels of specific proteins
pERK decrease decrease
pCREB decrease decrease
GAD67 increase increase
GFAP increase increase
Presence on Western blot of urea-soluble fraction of the brain extracts
Polyubiquitinated TDP-43 increase prominent increase
Phosphorylated TDP-43 absence absence
35 kD fragment of TDP-43 increase prominent increase
25 kD fragment of TDP-43 absence presence
TDP-43+ NCIs adjacent to TDP-43 depleted 
nuclei in Tg mouse brain sections
Immunohistochemistry absence presence
Presence of TDP-43+, ubiquitin+ NCIs Immunostaining absence presence
Hippocampus volume MRI measurement na decrease
Neuronal loss
Brain weight similar to WT decrease
Neuronal counts similar to WT decrease
Apoptosis TUNEL assay absence increase
na, not analyzed.1670 New mouse model of neurodegenerative disease | Tsai et al.
If a mouse stayed on the rod until the end of the 2 min trial, a time of 120 s 
was recorded.
Novel object recognition task. The experimental protocol previously 
described by Cao et al. (2008) was used. In brief, the mice were individually 
habituated to an open-field box for 3 d. During the training sessions, two 
novel objects were placed in the open field, and the animals were allowed to 
explore for 15 min. The time spent exploring each object was recorded. 
During the one-hour recall tests, the animals were placed back into the same 
box, in which one of the familiar objects from training was replaced by a 
novel object, and allowed to explore freely again for 15 min. The ratio of the 
time spent exploring any one of the two original objects (training session) or 
the novel object over the total time spent exploring both objects was used to 
measure the recognition function.
Western blotting. For analysis of the expression levels of different proteins 
(Fig. 1 C and Fig. 4 A), the extracts were prepared from the cerebral cortex, 
hippocampus, cerebellum, and spinal cord of the WT and male Tg mice of 
the age 2 mo by homogenization of the tissues in RIPA lysis buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1% Igepal CA-630, 2 mM EDTA, pH 8.0, 1 mM 
Na3VO4, 20 g/ml pepstatin A, 20 g/ml leupeptin, 20 g/ml aprotinin, 
1 mM PMSF, 50 mM NaF). The extracts were then analyzed by 8–12% SDS-
PAGE, followed by blot hybridization with one or more of the following anti-
bodies:  a  homemade  anti-TDP-43  (Wang  et  al.,  2008a),  antitubulin   
(Millipore), anti-CamKII (Millipore), anti-ERK (Millipore), anti-pERK 
(Millipore), anti-pCREB (Millipore), anti-GAD67 (Millipore), anti-GAP43 
(Millipore), anti-GFAP (Millipore), anti–protein kinase A (Millipore), and anti-
PGRN (R&D Systems), respectively. The relative intensities of the bands 
were normalized against that of the tubulin and expressed as means ± SEM.
For the sequential biochemical fractionation analysis, the forebrain tissue 
was dissected, weighed, and sequentially extracted with buffers of increasing 
strength as previously described (Neumann et al., 2006). In brief, the fore-
brains were extracted sequentially at 5 ml/g (vol/wt) with low-salt (LS) buffer 
(10 mM Tris, pH 7.5, 5 mM EDTA, 1 mM DTT, 10% sucrose, and a cock-
tail of protease inhibitors), high-salt Triton X-100 (TX) buffer (LS + 1% 
Triton X-100 + 0.5 M NaCl), myelin floatation buffer (TX buffer contain-
ing 30% sucrose), and sarkosyl (SARK) buffer (LS + 1% N-Lauroyl- 
sarcosine  +  0.5  M  NaCl).  The  SARK-insoluble  materials  were  further 
extracted in 0.25 ml/g urea buffer (7 M urea, 2 M thiourea, 4% 3-[(3-Chol-
amidopropyl)dimethylammonio]-1-propanesulfonate, 30 mM Tris, pH 8.5). 
The proteins in the urea-soluble samples were resolved by Tris-glycine/12% 
SDS-PAGE, transferred to nitrocellulose, and then probed with an anti-
TDP antibody (Protein Tech Group) that was used in similar experiments 
(Winton et al., 2008).
Immunostaining. Immunostaining was used to examine the expression 
patterns of TDP-43 and GAD67 in primary hippocampal neuron cultures of 
the WT and Tg mice. Cells were dissected from embryonic day 16.5   
embryos for culturing in Neuralbasal medium, and the cultured cells (DIV 14) 
were fixed with 4% paraformaldehyde (PFA). For staining, the cell were in-
cubated overnight with the individual primary antibodies against GAD67 
(1:500) and TDP-43 (1:100), respectively, in 1% donkey serum (D9663, 
Sigma) in PBS (phosphate buffered saline).
For immunofluorescence staining of the mouse brains, adult mice were 
anesthetized and perfused transcardially in PBS with 4% PFA. The brain was 
removed and then immersed in 4% PFA solution with 20% sucrose overnight. 
12-µm-thick sections were incubated with one or more of the following: 
anti–TDP-43  antibody  (one  was  previously  generated  in  our  laboratory 
[Wang et al., 2008b] and another was obtained from the Protein Tech 
Group), mouse monoclonal anti-GFAP (Millipore), mouse monoclonal anti-
ubiquitin (Millipore), mouse monoclonal anti-NeuN (Millipore), and the Alexa 
Fluor 488–conjugated goat anti–mouse antibodies (Invitrogen). The sections 
were then incubated with DAPI and coverslipped with the mounting   
medium (fluorescent mounting medium; Dako). All sections were examined 
in a laser scanning confocal microscope (LSM 510; Carl Zeiss, Inc.).
was then purified from pCaMKII-TDP-43 and injected into the one-cell 
embryos of FVB/N mice. The injected embryos were then transferred into 
the oviducts of surrogate mothers. 78 offsprings from the surrogate mother 
mice carrying the Cam KII-TDP-43 transgene-injected embryos were gen-
otyped,  and  10  of  them  were  identified  as  the  founders. These  FVB/N 
founders were bred with WT FVB/N mice, and three of them were germline 
transmitted. Each of the three germlines transmitted, CamKII-TDP-43 Tg 
lines were set to littermate intercrosses within the line so to obtain three ho-
mozygous TDP-43 Tg mouse lines. The homozygosity was determined by 
Southern blotting, and the overexpression of TDP-43 was confirmed by 
quantitative RT-PCR and Western blotting analyses of the forebrain tissues 
from 2-mo-old mice. All the mice were bred at the Animal Facility of the   
Institute of Molecular Biology (IMB), Academia Sinica, Taiwan. They were 
housed in a room maintained on a 12 h/12 h light/dark cycle (light on at 
7:00 a.m.) with continuous supply of food and water. Experimental proce-
dures for handling the mice were approved by the Institutional Animal Care 
and Utilization Committee, Academia Sinica.
For genotyping of the founders, both Southern blot analysis and PCR 
were performed according to the standard procedures. For Southern blot 
analysis, the genomic tail DNAs were digested with KpnI and hybridized 
with a 543 bp NotI fragment from pGEMT-TDP-43 (Promega). The   
genomic DNAs of the Tg CaMKII-TDP-43 mice would give rise to a 4.4-kb   
fragment on the blot. For PCR, the following primers were used: forward 
primer  5-GGCTTGAGATCTGGCCATACACT-3  and  reverse  primer 
5-TAAGATCTTTCTTGACCTGAACCATA-3. A 523-bp band on gel 
was expected for the Tg mice, but not the WT or NT mice. The breeding test 
was used to confirm the homozygosity of the Tg+/+ mice.
In situ hybridization. In situ hybridization was performed as described 
previously (Tsai et al., 2002), with minor modifications. 20-µm coronal sec-
tions were taken from the mouse brains serially, covering both the hippocam-
pus and cortex of the cerebrum. The antisense probe complementary to the 
sequence of the TDP-43 mRNA (5-GCTCTGAATGGTTTGGGAAT-
GAAGACATCTACCACT-3) and the corresponding sense probe were   
3 end-labeled with -[35S]dATP and hybridized, respectively, at 42°C for   
24 h with Poly-Prep slides (Sigma-Aldrich) containing the brain sections. 
After extensive washing, the slides were dehydrated with ethanol and ex-
posed to BioMax films (Kodak) for 10 d. The signals from the in situ hybrid-
ization were quantified by measuring the optic densities of the relevant fields 
with the use of the ImageJ program (National Institutes of Health).
Morris water maze task. For spatial learning test, the Morris water maze 
task was performed as described previously (Tsai et al., 2007). The animals 
were subjected to four trials per session and two sessions a day, with one session 
given in the morning and the other given in the afternoon. For a complete 
test, a total of 6 sessions in 3 d were given. The time spent by the individual 
mice to reach the platform in the water was recorded as the escape latency.
Fear conditioning task. For fear conditioning task, the mice were placed 
in a fear conditioning shock chamber (10 × 10 × 15 inches high) with multi-
parameter activity monitors. The conditioned stimulus (CS) used was an   
85-dB sound at 2,800 Hz, and the unconditioned stimulus (US) was a con-
tinuous scrambled foot shock at 0.75 mA.
Locomotor activity. Mouse movement was monitored by the TRuScan 
Digiscan system (Coulbourn Instruments, Inc.), which uses infrared beams 
to detect the horizontal and vertical movements. The pattern of the beam 
breaks was computerized to generate a quantitative measure of the locomotor 
activity. Each mouse was placed in the testing chamber for 5 min for adapta-
tion, followed by a 30-min recording for analysis of the total time moved.
Limb-clasping observation and rotarod test. The limb-clasping and 
rotarod tests were performed according to the procedures described by Hara 
et al. (2006). For the latter, the mice were placed on a rod rotating at   
20 r.p.m., and the time taken for them to fall from the rod was measured.   JEM VOL. 207, August 2, 2010 
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Sinica, Taiwan. The dates of birth and death of each mouse were recorded. 
The survival curves were drawn by the Kaplan and Meier method, and com-
pared by the Log-rank test.
Statistical analysis. All data are reported as the mean ± SEM. Independent 
experiments were compared by the Student’s t test. Differences, indicated by 
the asterisks, were considered statistically significant at P < 0.05.
Online supplemental material. Fig. S1 shows the levels of TDP-43 in the 
TDP-43 Tg+/+ and Tg+/ mice in comparison to the WT. Fig. S2 shows the 
water maze tests of CaMKII-TDP-43 Tg+/ mice in comparison to the WT, 
NT, and TDP-43 Tg+/+ mice. Fig. S3 shows the survival curves of the 
TDP-43 Tg+/+ and WT mice. Fig. S4 shows the histological analysis of the 
motor neurons in TDP-43 Tg+/+ mice. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20092164/DC1.
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